Scoliosis: Unmet Need Spawns Device Innovation
The once high-flying spine market has been brought down to earth recently as industrywide pressures from regulatory approval to payor reimbursement have altered the outlook on profits. These changes can be especially hard on specialized areas of the market such as the scoliosis field, where a great deal of innovation is still in the research stages at universities and start-up companies.
You may also be interested in...
Once considered the high flying segment of the musculoskeletal industry, the spine industry has finally hit a wall as procedure volumes stall, implant prices tumble, and payors push back on authorizing expensive operations for back pain such as spinal fusion. As economic woes heighten, hand in hand with persistent unemployment just as health care and regulatory reforms kick in, many left the North American Spine Society meeting in early October wondering where the bright spots are in this industry.
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.